| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $89,559 | 5 | 100 |
Sells | $0 | 0 | 0 |
| MATSUI CONNIE | director | 1 | $39,950 | 0 | $0 | $39,950 |
| Chow Gregory K. | CFO | 1 | $15,998 | 0 | $0 | $15,998 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | 1 | $13,607 | 0 | $0 | $13,607 |
| Chung Jane | Chief Executive Officer | 1 | $10,011 | 0 | $0 | $10,011 |
| Pauling David | Chief Admin. Ofcr. & GC | 1 | $9,993 | 0 | $0 | $9,993 |
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Sutro Biopharma, Inc. have bought $89,559 and sold $0 worth of Sutro Biopharma, Inc. stock.
On average, over the past 5 years, insiders at Sutro Biopharma, Inc. have bought $122,287 and sold $166,125 worth of stock each year.
Highest buying activity among insiders over the last 12 months: MATSUI CONNIE (director) — $39,950. Chow Gregory K. (CFO) — $15,998. Gerber Hans-Peter (CHIEF SCIENTIFIC OFFICER) — $13,607.
The last purchase of 12,500 shares for transaction amount of $10,011 was made by Chung Jane (Chief Executive Officer) on 2025‑10‑15.
| 2025-10-15 | Chung Jane | Chief Executive Officer | 12,500 0.0151% | $0.80 | $10,011 | +45.26% | ||
| 2025-10-15 | Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | 17,000 0.0206% | $0.80 | $13,607 | +45.26% | ||
| 2025-10-15 | Pauling David | Chief Admin. Ofcr. & GC | 12,504 0.0151% | $0.80 | $9,993 | +45.26% | ||
| 2025-10-15 | MATSUI CONNIE | director | 50,000 0.0604% | $0.80 | $39,950 | +45.26% | ||
| 2025-10-15 | Chow Gregory K. | CFO | 19,750 0.0242% | $0.81 | $15,998 | +45.26% | ||
| 2024-01-29 | Sale | Vasquez Nicki | CHIEF PORT. STRAT & ALNCE OFCR | 12,185 0.0202% | $5.00 | $60,925 | -24.45% | |
| 2023-08-28 | Sale | Shtylla Brunilda | Chief Business Officer | 15,428 0.0253% | $4.71 | $72,595 | -16.67% | |
| 2023-08-25 | Sale | Shtylla Brunilda | Chief Business Officer | 11,613 0.0191% | $4.59 | $53,282 | -14.35% | |
| 2022-03-14 | NEWELL WILLIAM J | CEO | 20,000 0.0428% | $7.75 | $155,016 | -20.05% | ||
| 2021-09-28 | Sale | Vasquez Nicki | Chief Port. Strat & Alnce Ofcr | 7,812 0.0168% | $18.62 | $145,449 | -56.52% | |
| 2021-01-26 | Sale | Hallam Trevor | Chief Scientific Officer | 4,786 0.0109% | $25.71 | $123,056 | -22.66% | |
| 2020-12-28 | Sale | Hallam Trevor | Chief Scientific Officer | 4,786 0.0079% | $13.36 | $63,964 | -11.14% | |
| 2020-11-27 | Sale | Hallam Trevor | Chief Scientific Officer | 4,786 0.0081% | $10.69 | $51,147 | +17.02% | |
| 2020-11-05 | Sale | Hallam Trevor | Chief Scientific Officer | 33,502 0.061% | $9.68 | $324,299 | +38.31% | |
| 2020-09-28 | Sale | Hallam Trevor | Chief Scientific Officer | 1,950 0.0053% | $10.26 | $20,013 | +91.08% | |
| 2020-09-18 | Sale | Freund John Gordon | director | 800,000 2.1944% | $12.00 | $9.6M | +65.94% | |
| 2020-09-11 | Sale | Freund John Gordon | director | 1M 2.6591% | $10.00 | $10M | +89.21% | |
| 2020-08-26 | Sale | Hallam Trevor | Chief Scientific Officer | 975 0.0026% | $9.04 | $8,818 | +101.61% | |
| 2020-08-19 | Sale | Freund John Gordon | director | 1M 2.5584% | $8.72 | $8.72M | +102.44% | |
| 2020-07-27 | Sale | Hallam Trevor | Chief Science Officer | 975 0.0026% | $8.06 | $7,858 | +124.43% |
| Chung Jane | Chief Executive Officer | 122850 1.443% | $3.11M | 1 | 0 | |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER | 71832 0.8438% | $1.82M | 1 | 0 | |
| Pauling David | Chief Admin. Ofcr. & GC | 71737 0.8426% | $1.81M | 1 | 0 | |
| MATSUI CONNIE | director | 50000 0.5873% | $1.26M | 1 | 0 | |
| Chow Gregory K. | CFO | 19750 0.232% | $499,477.50 | 1 | 0 | |
| Merck & Co., Inc. | 10 percent owner | 2723509 31.991% | $68.88M | 1 | 0 | <0.0001% |
| Freund John Gordon | director | 560053 6.5785% | $14.16M | 0 | 3 | |
| NEWELL WILLIAM J | CEO | 116525 1.3687% | $2.95M | 2 | 0 | +40.88% |
| Hallam Trevor | Chief Scientific Officer | 56117 0.6592% | $1.42M | 0 | 16 | |
| Vasquez Nicki | CHIEF PORT. STRAT & ALNCE OFCR | 12803 0.1504% | $323,787.87 | 0 | 2 | |
| MOLINA ARTURO MD | Chief Medical Officer | 12083 0.1419% | $305,579.07 | 1 | 0 | +101.81% |
| FITZPATRICK LINDA A | Chief People & Comm. Officer | 9007 0.1058% | $227,787.03 | 1 | 0 | +101.81% |
| Petree Daniel H | director | 192 0.0023% | $4,855.68 | 0 | 1 | |
| Shtylla Brunilda | Chief Business Officer | 0 0% | $0 | 0 | 2 |
$22,693,451 | 105 | 8.15% | $199.87M | |
$8,708,580 | 93 | -5.38% | $237.37M | |
$18,752,549 | 33 | -28.39% | $193.49M | |
$6,915,275 | 21 | -32.61% | $227.68M | |
$4,701,608 | 14 | -4.34% | $210.7M | |
$1,037,470 | 13 | 78.00% | $202.03M | |
$6,847,110 | 9 | 5.96% | $195.24M | |
$145,296,407 | 8 | -0.98% | $216.84M | |
$99,355,998 | 7 | -65.74% | $200.5M | |
$5,905,507 | 7 | 2.69% | $215.11M | |
$272,982 | 6 | -28.53% | $227.31M | |
$8,286,963 | 6 | 3.09% | $212.13M | |
Sutro Biopharma, Inc. (STRO) | $20,729,984 | 5 | 51.71% | $215.3M |
$556,839 | 5 | 13.42% | $225.32M | |
$6,049,986 | 4 | -8.38% | $231.77M | |
$32,007,657 | 4 | -45.65% | $223.76M | |
$32,289,200 | 3 | -5.46% | $220.73M | |
$16,003,671 | 3 | 55.38% | $219.94M | |
$12,750 | 2 | -39.73% | $195.5M |
| Increased Positions | 26 | +19.26% | 2M | +32.2% |
| Decreased Positions | 62 | -45.93% | 1M | -27.41% |
| New Positions | 11 | New | 872,516 | New |
| Sold Out Positions | 34 | Sold Out | 849,951 | Sold Out |
| Total Postitions | 99 | -26.67% | 6M | +4.79% |
| Suvretta Capital Management, Llc | $7,111.00 | 7.21% | 648,832 | 0 | 0% | 2025-09-30 |
| Kynam Capital Management, Lp | $5,577.00 | 5.65% | 508,810 | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $4,959.00 | 5.03% | 452,435 | -20,789 | -4.39% | 2025-09-30 |
| Vanguard Group Inc | $4,037.00 | 4.09% | 368,299 | -43,226 | -10.5% | 2025-09-30 |
| Acadian Asset Management Llc | $3,715.00 | 3.77% | 338,932 | +34,708 | +11.41% | 2025-09-30 |
| Velan Capital Investment Management Lp | $3,420.00 | 3.47% | 312,000 | +6,000 | +1.96% | 2025-09-30 |
| Tang Capital Management Llc | $3,100.00 | 3.14% | 282,872 | +26,713 | +10.43% | 2025-09-30 |
| Merck & Co., Inc. | $2,985.00 | 3.03% | 272,351 | 0 | 0% | 2025-09-30 |
| Vestal Point Capital, Lp | $2,850.00 | 2.89% | 260,000 | 0 | 0% | 2025-09-30 |
| Eversept Partners, Lp | $2,511.00 | 2.55% | 229,131 | -95 | -0.04% | 2025-09-30 |